Like all the other assets of his specialty pharmaceuticals company, Alfred Altomari, the newly appointed CEO of Princeton, NJ-based Barrier Therapeutics, hails from Johnson & Johnson. Altomari was intrigued by the concept behind the fledgling company: commercializing innovative dermatological products that had been abandoned by J&J due to their limited market potential -- limited, that is, by Big Pharma standards. The skin business, however, wasn't always smooth. In 2005, two pipeline setbacks sent Barrier's stock price tumbling into the single digits, where it remains today. Altomari, who took the helm at Barrier in March, is now charged with shepherding its remaining drug candidates to market and steering the company -- which reported a loss of $46 million on revenues of $29.7 million in 2007 -- out of the red zone.
Pages to are hidden for
"Skin Deep"Please download to view full document